Cannabis Science CEO Unveils Loyalty Gift Procedure at 12:00 NOON PDT and Releases Development Updates on the 360,000 Sq. Ft. Nevada Research Complex Including University, Cultivation Centers, Formulation Laboratory, and Medical Clinic
(firmenpresse) - COLORADO SPRINGS, CO -- (Marketwired) -- 04/11/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today CEO Raymond C. Dabney releases the "Loyalty Gift" procedure on the CBIS website at NOON, Pacific Today. The website will allow individuals to login and submit information and documentation to receive their "Loyalty Gift" directly from Mr. Dabney''s personal holdings.
The Company has just received the first schematics renderings of the 360,000 Sq. Ft. Nevada Compound. The property development project and projected build outs will be further vetted out to include detailed land parcel assignments and proposed University and medical complex renderings. The Company has received serious requests expressing interest in the development complex and the Company has been speaking with several individuals/entities interested in participating in the development process. The released renderings will include parcel allocation and the company is very pleased with the rapid projected progress to fill these parcels, as it is talking with interested parties daily. Once the final plans are ready for public viewing, the Company will release the full property details along with the completed renderings and land plot assignments for the University, medical facility, cultivation centers, and Laboratory.
"This is a very special time and I want to extend my personal ''Thanks'' to everyone who has supported me throughout the years. I have been blessed with ''Very Loyal People'' who have supported me for years on end. I will recognize your names, and I look forward to reconnecting with many of you via phone. I have lost contact with some of you and you know who you are, I will be reaching out to you as well. Each of you are included in this ''Personal Thank You Gift'', whether you own CBIS Shares or not. Again Thank YOU All, for your confidence, your support, and your Loyalty throughout the years. For this Loyalty I will be ''Giving you some of my personal shares'' of Cannabis Science Inc. This is my personal confirmation of my Appreciation of you and your Loyalty. To the CBIS shareholders that I will ''Gift some of my Shares'', I want and expect nothing in return, as a matter of fact, in the future everyone can look forward to ''more Loyalty Gifts'' as we progress forward with our High-Growth Business Models in our group of Companies," stated Mr. Raymond C. Dabney, President, CEO, & Co-Founder of Cannabis Science Inc.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company''s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ''safe harbor'' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company''s reports filed with the Securities and Exchange Commission.
Cannabis Science, Inc.
Investor Relations
Teresa Misenheimer
Tel: 1-888-263-0832
Cannabis Science, Inc.
Mr. Raymond C. Dabney
Director, President & CEO, Co-Founder
Tel:1-888-263-0832
Cannabis Science, Inc.
Mr. Robert Kane
Director & CFO
Tel: 1-888-263-0832
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.04.2016 - 07:19 Uhr
Sprache: Deutsch
News-ID 1427171
Anzahl Zeichen: 2528
contact information:
Contact person:
Town:
COLORADO SPRINGS, CO
Phone:
Kategorie:
Alternative
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 272 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cannabis Science CEO Unveils Loyalty Gift Procedure at 12:00 NOON PDT and Releases Development Updates on the 360,000 Sq. Ft. Nevada Research Complex Including University, Cultivation Centers, Formulation Laboratory, and Medical Clinic
"
steht unter der journalistisch-redaktionellen Verantwortung von
Cannabis Science, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
